These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
414 related articles for article (PubMed ID: 33447034)
1. Gene Therapy for Drug-Resistant Glioblastoma via Lipid-Polymer Hybrid Nanoparticles Combined with Focused Ultrasound. Yang Q; Zhou Y; Chen J; Huang N; Wang Z; Cheng Y Int J Nanomedicine; 2021; 16():185-199. PubMed ID: 33447034 [TBL] [Abstract][Full Text] [Related]
2. Enhanced delivery of paclitaxel liposomes using focused ultrasound with microbubbles for treating nude mice bearing intracranial glioblastoma xenografts. Shen Y; Pi Z; Yan F; Yeh CK; Zeng X; Diao X; Hu Y; Chen S; Chen X; Zheng H Int J Nanomedicine; 2017; 12():5613-5629. PubMed ID: 28848341 [TBL] [Abstract][Full Text] [Related]
3. A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival. Kim SS; Rait A; Kim E; Pirollo KF; Nishida M; Farkas N; Dagata JA; Chang EH ACS Nano; 2014 Jun; 8(6):5494-514. PubMed ID: 24811110 [TBL] [Abstract][Full Text] [Related]
4. Overcoming the Blood-Brain Tumor Barrier with Docetaxel-Loaded Mesoporous Silica Nanoparticles for Treatment of Temozolomide-Resistant Glioblastoma. Hsu TI; Chen YP; Zhang RL; Chen ZA; Wu CH; Chang WC; Mou CY; Chan HW; Wu SH ACS Appl Mater Interfaces; 2024 May; 16(17):21722-21735. PubMed ID: 38629735 [TBL] [Abstract][Full Text] [Related]
5. CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma. Zhao J; Cui X; Zhan Q; Zhang K; Su D; Yang S; Hong B; Wang Q; Ju J; Cheng C; Li C; Wan C; Wang Y; Zhou J; Kang C Theranostics; 2024; 14(7):2835-2855. PubMed ID: 38773970 [No Abstract] [Full Text] [Related]
6. Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma. Lan Y; Li X; Liu B; Lu J; Zuo B; Wang Y; Cao S; Fu X; Yue Q; Luo X; Zhong X; Dong Y; Wang Z; Yang T; Xie X; Zeng T; Zhang M; Wang Y; Shen Y; Zuo H; Zhao Y; Zhang C; Guo H Drug Resist Updat; 2024 Sep; 76():101122. PubMed ID: 39079407 [TBL] [Abstract][Full Text] [Related]
7. Nano-Codelivery of Temozolomide and siPD-L1 to Reprogram the Drug-Resistant and Immunosuppressive Microenvironment in Orthotopic Glioblastoma. Liu D; Cheng Y; Qiao S; Liu M; Ji Q; Zhang BL; Mei QB; Zhou S ACS Nano; 2022 May; 16(5):7409-7427. PubMed ID: 35549164 [TBL] [Abstract][Full Text] [Related]
8. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma. Chen Z; Wei X; Shen L; Zhu H; Zheng X Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207 [TBL] [Abstract][Full Text] [Related]
9. Concurrent blood-brain barrier opening and local drug delivery using drug-carrying microbubbles and focused ultrasound for brain glioma treatment. Ting CY; Fan CH; Liu HL; Huang CY; Hsieh HY; Yen TC; Wei KC; Yeh CK Biomaterials; 2012 Jan; 33(2):704-12. PubMed ID: 22019122 [TBL] [Abstract][Full Text] [Related]
10. Dual-targeted delivery of temozolomide by multi-responsive nanoplatform via tumor microenvironment modulation for overcoming drug resistance to treat glioblastoma. Chen X; Zheng Y; Zhang Q; Chen Q; Chen Z; Wu D J Nanobiotechnology; 2024 May; 22(1):264. PubMed ID: 38760771 [TBL] [Abstract][Full Text] [Related]
11. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma. Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606 [TBL] [Abstract][Full Text] [Related]
13. Focused Ultrasound-Mediated Blood-Brain Barrier Opening Increases Delivery and Efficacy of Etoposide for Glioblastoma Treatment. Wei HJ; Upadhyayula PS; Pouliopoulos AN; Englander ZK; Zhang X; Jan CI; Guo J; Mela A; Zhang Z; Wang TJC; Bruce JN; Canoll PD; Feldstein NA; Zacharoulis S; Konofagou EE; Wu CC Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):539-550. PubMed ID: 33346092 [TBL] [Abstract][Full Text] [Related]
14. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting. Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456 [TBL] [Abstract][Full Text] [Related]
15. Enhancing Boron Uptake in Brain Glioma by a Boron-Polymer/Microbubble Complex with Focused Ultrasound. Fan CH; Wang TW; Hsieh YK; Wang CF; Gao Z; Kim A; Nagasaki Y; Yeh CK ACS Appl Mater Interfaces; 2019 Mar; 11(12):11144-11156. PubMed ID: 30883079 [TBL] [Abstract][Full Text] [Related]
16. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells. Kato T; Natsume A; Toda H; Iwamizu H; Sugita T; Hachisu R; Watanabe R; Yuki K; Motomura K; Bankiewicz K; Wakabayashi T Gene Ther; 2010 Nov; 17(11):1363-71. PubMed ID: 20520650 [TBL] [Abstract][Full Text] [Related]
17. Overexpression miR-486-3p Promoted by Allicin Enhances Temozolomide Sensitivity in Glioblastoma Via Targeting MGMT. Wu H; Li X; Zhang T; Zhang G; Chen J; Chen L; He M; Hao B; Wang C Neuromolecular Med; 2020 Sep; 22(3):359-369. PubMed ID: 32086739 [TBL] [Abstract][Full Text] [Related]
18. Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O Chang KY; Hsu TI; Hsu CC; Tsai SY; Liu JJ; Chou SW; Liu MS; Liou JP; Ko CY; Chen KY; Hung JJ; Chang WC; Chuang CK; Kao TJ; Chuang JY Redox Biol; 2017 Oct; 13():655-664. PubMed ID: 28822335 [TBL] [Abstract][Full Text] [Related]
19. Chemotherapy sensitization of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes. Papachristodoulou A; Signorell RD; Werner B; Brambilla D; Luciani P; Cavusoglu M; Grandjean J; Silginer M; Rudin M; Martin E; Weller M; Roth P; Leroux JC J Control Release; 2019 Feb; 295():130-139. PubMed ID: 30537486 [TBL] [Abstract][Full Text] [Related]